BioRestorative Therapies Suspends Shipments of ExoCR and BioX Lines

What Happened BioRestorative Therapies, Inc. (BRTX) announced in a Form 8-K filed August 14, 2026, that on August 7, 2026 it suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines — specifically its ExoCR products and its BioX products — pending a business review and regulatory assessment. The company said it has not decided to discontinue these product lines and is reviewing documentation, sourcing, and the regulatory status associated with them. The filing also includes the company’s forward-looking statements about the review and potential outcomes.

Key Details

• Suspension effective: August 7, 2026; reported in Form 8-K filed August 14, 2026 (Item 8.01, Other Events).
• Affected products: ExoCR product line and BioX product line (all orders and shipments suspended).
• Scope of review: documentation, sourcing, and regulatory status; company has not decided to discontinue the lines.
• Risks noted: ability to resume sales, costs from suspension, potential need for additional capital; forward-looking statements reference the 2025 Form 10-K.

Why It Matters Suspending orders and shipments can directly reduce near-term product revenue and affect cash flow until the review is completed and sales can resume. The company flagged that resuming sales is uncertain and that the suspension could lead to costs or a need for additional capital — items material to investors. This filing is an early disclosure of operational and regulatory risk for BRTX’s biocosmeceutical business; investors should watch for updates on the company’s review, regulatory findings, and any impact on financial guidance or liquidity.